If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Emgality ® (galcanezumab-gnlm) injection
100 mg/mL, 120 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is there an EMGALITY® (galcanezumab-gnlm) pregnancy registry?
An Emgality (galcanezumab) pregnancy registry is currently under review with the United States Food and Drug Administration.
A galcanezumab pregnancy registry is currently under review with the United States Food and Drug Administration.
Pregnancy or related events can be reported to
the Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov/medwatch, or
Enclosed Prescribing Information
EMGALITY® (galcanezumab-gnlm) injection, for subcutaneous use, Lilly
Date of Last Review: May 09, 2019
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 8am - 7pm ET
